特发性肺纤维化市场：依药物、给药途径、通路及地区划分

特发性肺纤维化市场规模预计在 2025 年为 49.5 亿美元，预计到 2032 年将达到 88.759 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 8.7%。

特发性肺纤维化 (IPF) 是一种特殊类型的慢性、进行性纤维化间质性肺炎，病因不明，主要影响老年人的肺部，其组织病理学和/或放射学特征与进行性间质性肺炎 (UIP) 相似。 IPF 的诊断需要排除其他类型的间质性肺炎，包括其他特发性间质性肺炎 (IIP) 以及与环境暴露、药物或结缔组织疾病相关的间质性肺部疾病 (ILD)。

市场动态

特发性肺纤维化盛行率的不断上升预计将推动市场成长。例如，根据美国国家医学图书馆2021年7月发布的报告，2020年全球特发性肺纤维化的盛行率为每10万人13-20人。在美国，2020年约有10万人受其影响，每年诊断出3万至4万例新病例。

印度国家生物技术资讯中心发布的报告显示，2021年，印度特发性肺纤维化的盛行率将达到13.7%左右。

此外，特发性肺纤维化盛行率的不断上升促使主要市场参与者专注于推出新产品，预计这将在预测期内推动市场成长。例如，2022年5月，学名药和生物相似药领域的全球领导者山德士宣布将在美国特发性Pirfenidone的仿製药。吡非尼酮是第一个获得AB类上市许可（完全可互换）的抗体药物，与生物技术公司基因泰克的Esbriet等效，用于治疗特发性肺纤维化(IPF)患者。该学名药药物将透过专科药房开立处方给患者。

本次调查的主要特点

• 本报告对全球特发性肺纤维化市场进行了详细分析，并以 2024 年为基准年，提供了预测期 2025-2032 的市场规模（百万美元）和年复合成长率（CAGR%）。
• 它还揭示了各个领域的潜在商机，并解释了该市场有吸引力的投资提案矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
• 本研究基于公司亮点、产品系列、关键亮点、财务绩效和策略等参数，对全球特发性肺纤维化市场的主要企业进行了分析。本研究涵盖的主要企业包括基因泰克公司 (Genentech, Inc.)、阿斯特捷利康 (AstraZeneca)、Blade Therapeutics、百时美施贵宝公司 (Bristol-Myers Squibb Company)、西普拉公司 (Cipla Inc.)、罗氏製药公司 (F. Hoffmann-La Roche)、西普拉公司 (Cipla Inc.)、罗氏製药公司 (F. Hoffmann-La Roche)、默克理克 (Ciplaim)、Gicicoan (F. Hoffmann-La Roche)、默克理克公司 (Nicigos) 公司、加拉瓦戈斯公司 (Micico)、默克科Co., Inc.)、Promedior 公司、Prometic Life Sciences 公司、大熊製药 (印度) 私人有限公司 (Daewoong Pharmaceutical (India) Pvt Ltd)、山德士国际有限公司 (Sandoz International GmbH，诺华公司) 和 Algernon Pharmaceuticals 公司。
• 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、规模扩大、市场扩张和行销策略做出明智的决策。
• 全球特发性肺纤维化市场报告涉及该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员将透过用于分析全球特发性肺纤维化市场的各种策略矩阵更轻鬆地做出决策。

目录

第一章：调查目标和先决条件

• 调查目的
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章：市场动态、法规与趋势分析

• 市场动态
  • 驱动程式
  • 抑制因素
  • 市场吸引力分析
  • 市场机会
  • 产品发布
  • 合併、收购与合作
  • 监理指南与合规性
  • 主要进展
  • 市场趋势
  • PEST分析
  • 流行病学
  • 波特分析
  • 监管情景
  • 品牌分析
  • 定价分析
  • 管道分析

4. 2020 年至 2032 年全球特发性肺纤维化市场（依药物划分）

• Pirfenidone
• 尼达尼布
• 其他（干扰素γ-1b等）

5. 全球特发性肺纤维化市场（依给药途径），2020 年至 2032 年

• 口服
• 肠外

6. 2020-2032 年全球特发性肺纤维化市场（按通路）

• 医院药房
• 零售药局
• 网路药局

7. 2020 年至 2032 年全球特发性肺纤维化市场（按地区）

• 北美洲
  • 美国
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
• 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 其他亚太地区
• 中东
  • GCC
  • 以色列
  • 其他中东地区
• 非洲
  • 北非
  • 中部非洲
  • 南非

第八章 竞争态势

• Genentech, Inc.
• Boehringer Ingelheim International GmbH.
• Avalyn Pharma, Inc.
• AstraZeneca
• Blade Therapeutics
• Bristol-Myers Squibb Company
• Cipla Inc.
• F. Hoffmann-La Roche
• FibroGen, Inc.
• Galapagos NV
• MediciNova, Inc.
• Merck & Co., Inc.
• Promedior, Inc.
• Prometic Life Sciences Inc.
• Daewoong Pharmaceutical（India）Pvt Ltd.
• Sandoz International GmbH（Novartis）
• Algernon Pharmaceuticals Inc.

第九章 章节

• 调查方法
• 关于出版商

Idiopathic Pulmonary Fibrosis Market is estimated to be valued at USD 4,950 Mn in 2025 and is expected to reach USD 8,875.9 Mn by 2032, growing at a compound annual growth rate (CAGR) of 8.7% from 2025 to 2032.

Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause that occurs primarily in older adults, in the lungs, and is associated with the histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP). The diagnosis of IPF requires exclusion of other forms of interstitial pneumonia including other idiopathic interstitial pneumonias (IIP) and interstitial lung disease (ILD) associated with environmental exposure, medication, or connective tissue disease.

Market Dynamics

Increasing prevalence of Idiopathic pulmonary fibrosis is expected to drive the market growth. For instance, in July 2021, according to the report published by National Library of Medicine, the prevelance of idiopathic pulmonary fibrosis was 13 to 20 per 100,000 people worldwide in 2020. About 100,000 people were affected in the U.S., in 2020, whereas 30,000 to 40,000 new cases are diagnosed every year.

According to the report published by National Center for Biotechnology Information, the prevalence of Idiopathic pulmonary fibrosis in India was found to be approximately 13.7% in 2021.

Furthermore, due to increasing prevalence of Idiopathic pulmonary fibrosis, the key market players are focusing on new product launches, and this is expected to drive the market growth over the forecast period. For instance, in May 2022, Sandoz, a global leader in generic and biosimilar medicines, announced the launch of its generic Pirfenidone in the U.S., the first AB-rated (Antibody)(fully substitutable) equivalent to Genentech's, a biotechnology company, Esbriet, to treat patients with idiopathic pulmonary fibrosis (IPF). This oral medicine is prescribed to patients via specialty pharmacies.

Key features of the study

• This report provides in-depth analysis of the global Idiopathic pulmonary fibrosis market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global Idiopathic pulmonary fibrosis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies Key companies covered as a part of this study include Genentech, Inc., Boehringer Ingelheim International GmbH, Avalyn Pharma, Inc., AstraZeneca, Blade Therapeutics, Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche, FibroGen, Inc., Galapagos NV, MediciNova, Inc., Merck & Co., Inc., Promedior, Inc., Prometic Life Sciences Inc., Daewoong Pharmaceutical (India) Pvt Ltd, Sandoz International GmbH (Novartis), and Algernon Pharmaceuticals Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global Idiopathic pulmonary fibrosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Idiopathic pulmonary fibrosis market.

Market Segmentation

• Global Idiopathic pulmonary fibrosis market, By Drug
  • Pirfenidone
  • Nintedanib
  • Others (Interferon gamma-1b and Others)
• Global Idiopathic pulmonary fibrosis market, By Route of Administration
  • Oral
  • Parenteral
• Global Idiopathic pulmonary fibrosis market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Idiopathic pulmonary fibrosis market, By Region
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Genentech, Inc.
  • Boehringer Ingelheim International GmbH
  • Avalyn Pharma, Inc.
  • AstraZeneca
  • Blade Therapeutics
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Hoffmann-La Roche
  • FibroGen, Inc.
  • Galapagos NV
  • MediciNova, Inc.
  • Merck & Co., Inc.
  • Promedior, Inc.
  • Prometic Life Sciences Inc.
  • Daewoong Pharmaceutical (India) Pvt Ltd.
  • Sandoz International GmbH (Novartis)
  • Algernon Pharmaceuticals Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Attractiveness Analysis
  • Market Opportunities
  • Product Launches
  • Merger, Acquisition, Collaboration
  • Regulatory Guideline and Compliances
  • Key Developments
  • Market Trends
  • PEST Analysis
  • Epidemiology
  • PORTER's Analysis
  • Regulatory Scenario
  • Brand Analysis
  • Pricing Analysis
  • Pipeline Analysis

4. Global Idiopathic Pulmonary Fibrosis Market, By Drug, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Pirfenidone
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Nintedanib
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Others (Interferon gamma-1b and Others)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Idiopathic Pulmonary Fibrosis Market, By Route of Administration, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segments Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Idiopathic Pulmonary Fibrosis Market, By Region, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-Region, 2020 - 2032, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Genentech, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Boehringer Ingelheim International GmbH.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Avalyn Pharma, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Blade Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Cipla Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• F. Hoffmann-La Roche
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• FibroGen, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Galapagos NV
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
• MediciNova, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Promedior, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Prometic Life Sciences Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Daewoong Pharmaceutical (India) Pvt Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sandoz International GmbH (Novartis)
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Algernon Pharmaceuticals Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

9. Section

• Research Methodology
• About Us